Literature DB >> 22733945

The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using National Joint Registry Data.

S S Jameson1, P N Baker, S C Charman, D J Deehan, M R Reed, P J Gregg, J H Van der Meulen.   

Abstract

We compared thromboembolic events, major haemorrhage and death after knee replacement in patients receiving either aspirin or low-molecular-weight heparin (LMWH). Data from the National Joint Registry for England and Wales were linked to an administrative database of hospital admissions in the English National Health Service. A total of 156,798 patients between April 2003 and September 2008 were included and followed for 90 days. Multivariable risk modelling was used to estimate odds ratios adjusted for baseline risk factors (AOR). An AOR < 1 indicates that risk rates are lower with LMWH than with aspirin. In all, 36,159 patients (23.1%) were prescribed aspirin and 120,639 patients (76.9%) were prescribed LMWH. We found no statistically significant differences between the aspirin and LMWH groups in the rate of pulmonary embolism (0.49% vs 0.45%, AOR 0.88 (95% confidence interval (CI) 0.74 to 1.05); p = 0.16), 90-day mortality (0.39% vs 0.45%, AOR 1.13 (95% CI 0.94 to 1.37); p = 0.19) or major haemorrhage (0.37% vs 0.39%, AOR 1.01 (95% CI 0.83 to 1.22); p = 0.94). There was a significantly greater likelihood of needing to return to theatre in the aspirin group (0.26% vs 0.19%, AOR 0.73 (95% CI 0.58 to 0.94); p = 0.01). Between patients receiving LMWH or aspirin there was only a small difference in the risk of pulmonary embolism, 90-day mortality and major haemorrhage. These results should be considered when the existing guidelines for thromboprophylaxis after knee replacement are reviewed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733945     DOI: 10.1302/0301-620X.94B7.29129

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  11 in total

1.  Anterior and Anterolateral Approaches for THA Are Associated With Lower Dislocation Risk Without Higher Revision Risk.

Authors:  Dhiren Sheth; Guy Cafri; Maria C S Inacio; Elizabeth W Paxton; Robert S Namba
Journal:  Clin Orthop Relat Res       Date:  2015-11       Impact factor: 4.176

Review 2.  [Aspirin and venous thromboses].

Authors:  K Schrör
Journal:  Internist (Berl)       Date:  2015-01       Impact factor: 0.743

3.  Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?

Authors:  Abiram Bala; James I Huddleston; Stuart B Goodman; William J Maloney; Derek F Amanatullah
Journal:  Clin Orthop Relat Res       Date:  2017-05-31       Impact factor: 4.176

4.  American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Authors:  David R Anderson; Gian Paolo Morgano; Carole Bennett; Francesco Dentali; Charles W Francis; David A Garcia; Susan R Kahn; Maryam Rahman; Anita Rajasekhar; Frederick B Rogers; Maureen A Smythe; Kari A O Tikkinen; Adolph J Yates; Tejan Baldeh; Sara Balduzzi; Jan L Brożek; Itziar Etxeandia- Ikobaltzeta; Herman Johal; Ignacio Neumann; Wojtek Wiercioch; Juan José Yepes-Nuñez; Holger J Schünemann; Philipp Dahm
Journal:  Blood Adv       Date:  2019-12-10

5.  Time-varying impact of comorbidities on mortality after liver transplantation: a national cohort study using linked clinical and administrative data.

Authors:  Chutwichai Tovikkai; Susan C Charman; Raaj K Praseedom; Alexander E Gimson; Jan van der Meulen
Journal:  BMJ Open       Date:  2015-05-14       Impact factor: 2.692

Review 6.  Aspirin and the prevention of venous thromboembolism following total joint arthroplasty: commonly asked questions.

Authors:  I Azboy; R Barrack; A M Thomas; F S Haddad; J Parvizi
Journal:  Bone Joint J       Date:  2017-11       Impact factor: 5.082

7.  Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service.

Authors:  Dalia M Dawoud; David Wonderling; Jessica Glen; Sedina Lewis; Xavier L Griffin; Beverley J Hunt; Gerard Stansby; Michael Reed; Nigel Rossiter; Jagjot Kaur Chahal; Carlos Sharpin; Peter Barry
Journal:  Front Pharmacol       Date:  2018-11-27       Impact factor: 5.810

8.  CRISTAL: protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study.

Authors:  Verinder Singh Sidhu; Steven E Graves; Rachelle Buchbinder; Justine Maree Naylor; Nicole L Pratt; Richard S de Steiger; Beng H Chong; Ilana N Ackerman; Sam Adie; Anthony Harris; Amber Hansen; Maggie Cripps; Michelle Lorimer; Steve Webb; Ornella Clavisi; Elizabeth C Griffith; Durga Anandan; Grace O'Donohue; Thu-Lan Kelly; Ian A Harris
Journal:  BMJ Open       Date:  2019-11-06       Impact factor: 2.692

9.  PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients.

Authors:  Robert V O'Toole; Deborah M Stein; Katherine P Frey; Nathan N O'Hara; Daniel O Scharfstein; Gerard P Slobogean; Tara J Taylor; Bryce E Haac; Anthony R Carlini; Theodore T Manson; Kuladeep Sudini; C Daniel Mullins; Stephen T Wegener; Reza Firoozabadi; Elliott R Haut; Michael J Bosse; Rachel B Seymour; Martha B Holden; Ida Leah Gitajn; Samuel Z Goldhaber; Alexander L Eastman; Gregory J Jurkovich; Heather A Vallier; Joshua L Gary; Conor P Kleweno; Joseph Cuschieri; Debra Marvel; Renan C Castillo
Journal:  BMJ Open       Date:  2021-03-24       Impact factor: 2.692

10.  Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement.

Authors:  S S Jameson; P N Baker; D J Deehan; A Port; M R Reed
Journal:  Bone Joint Res       Date:  2014-05       Impact factor: 5.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.